What is Molecular Assemblies?
Headquartered in San Diego, Molecular Assemblies is a pioneering life sciences enterprise focused on the development of enzymatic DNA synthesis technology. By replicating the biological processes inherent in nature, the company produces long, sequence-specific DNA that is both reliable and cost-effective. This technological breakthrough is positioned to serve as a foundational element for diverse sectors, including industrial synthetic biology, precision medicine, and the burgeoning field of DNA-based data storage. By moving away from traditional, resource-intensive chemical synthesis, Molecular Assemblies is establishing a new standard for sustainability and precision in the biotechnology landscape.
How much funding has Molecular Assemblies raised?
Molecular Assemblies has raised a total of $57.1M across 6 funding rounds:
Private Equity
$4.5M
Angel/Seed
$2.3M
Debt
$150K
Debt
$325K
Series A
$24M
Series B
$25.8M
Private Equity (2016): $4.5M, investors not publicly disclosed
Angel/Seed (2016): $2.3M led by 11.2 Capital, Alexandria Venture Investments, Genomics Investment Syndicate, Cavendish Impact Capital Fund, Agilent Technologies, and Newport Holdings, LP
Debt (2020): $150K supported by PPP
Debt (2021): $325K featuring PPP
Series A (2021): $24M backed by Agile Technologies, Argonautic Ventures, Alexandria Venture Investments, LYFE Capital, Codexis, and iSelect Fund Management
Series B (2022): $25.8M with participation from Codexis, LYFE Capital, Argonautic Ventures, iSelect Fund Management, Agilent, and Casdin Capital
Key Investors in Molecular Assemblies
Casdin Capital
Casdin Capital is a specialized investment firm with deep expertise in the life sciences sector, focusing on financing the next generation of molecular information and diagnostic pioneers.
Agilent Technologies
Agilent Technologies is a global leader in life sciences and diagnostics, providing advanced instrumentation and services that support pharmaceutical development and research innovation.
LYFE Capital
LYFE Capital is a premier healthcare investment platform that connects high-potential healthcare companies with global markets and strategic supply chain partners.
What's next for Molecular Assemblies?
With the support of its latest strategic investment, Molecular Assemblies is well-positioned to scale its operations and accelerate the integration of its enzymatic synthesis platform into global supply chains. The company is expected to focus on expanding its manufacturing capabilities to meet the growing demand for high-fidelity DNA in therapeutic development and diagnostic applications. As the firm transitions from development to broader commercial deployment, it will likely prioritize strategic partnerships with industry leaders in biotherapeutics and data storage to solidify its market position. The focus remains on refining the scalability of its proprietary technology to ensure that the next generation of DNA-based products is accessible, affordable, and produced with minimal environmental impact.
See full Molecular Assemblies company page
